Gastric or Gastro-oesophageal Junction Adenocarcinoma (GC/GEJC)

Active Ingredient: Durvalumab

Indication for Durvalumab

Population group: only adults (18 years old or older)
Therapeutic intent: Adjuvant - intent

Durvalumab in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, is indicated for the treatment of adults with resectable gastric or gastro-oesophageal junction adenocarcinoma.

For this indication, competent medicine agencies globally authorize below treatments:

1,500 mg every 4 weeks for up to 2 κύκλους prior to surgery, 1,500 mg every 4 weeks for up to 12 cycles after surgery

For:

Dosage regimens

In the case that patient weight is > 30 kg and from cycle 1 until cycle 12 :

Intravenous, 1,500 milligrams durvalumab, once every 4 weeks.

Detailed description

Recommended durvalumab dose:

1 500 mg* in combination with FLOT chemotherapy every 4 weeks for up to 2 cycles prior to surgery, followed by 1 500 mg*, with FLOT chemotherapy, every 4 weeks for up to 2 cycles and then as 1 500 mg monotherapy every 4 weeks for up to 10 cycles, for a total of up to 12 cycles after surgery.

* GC/GEJC patients with a body weight of 30 kg or less must receive weight-based dosing of durvalumab at 20 mg/kg.

Duration of therapy

Neoadjuvant phase: until disease progression that precludes definitive surgery or unacceptable toxicity.

Adjuvant phase: until progression or recurrence, unacceptable toxicity, or a maximum of 12 cycles after surgery.

Dosage considerations

When durvalumab is administered in combination with chemotherapy, administer durvalumab prior to chemotherapy on the same day.

Active ingredient

Durvalumab

Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Durvalumab does not induce antibody dependent cell-mediated cytotoxicity (ADCC). Selective blockade of PD-L1/PD-1 and PD-L1/CD80 interactions enhances antitumour immune responses and increases T-cell activation.

Read more about Durvalumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.